MYC is a gene that controls normal cell growth, but when it is mutated or amplified in cancer, it sets off a chain reaction that helps tumors grow uncontrollably. While there is currently no specific way to target it, previous research has focused on blocking other steps in the chain as a workaround to impede tumor growth. The team, led by Constantinos Koumenis, PhD, the Richard Chamberlain Professor of Radiation Oncology and vice chair and research division director of Radiation Oncology, have previously shown that in certain tumors, one of these steps is regulated by a kinase called PERK, which activates ATF4. However, in this new study, they've shown that blocking PERK does not always stop tumor growth because MYC actually controls a second process that can work in parallel as a redundancy in the system. This study identified this second kinase, which is called GCN2.

"What we've learned is that we need to go further downstream to block tumor growth in a way that cancer cells can't easily escape, and our study identifies the target to do just that," said Koumenis, who is the co-senior author on this study along with Davide Ruggero, PhD, a professor of Urology in the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF).

This study shows the alternative approach is to target ATF4 itself, since it's the point where both signal pathways converge, meaning there's less redundancy built in to allow cancer to survive. The findings also show that ATF4 turns on the genes MYC needs for growth and also controls the rate at which cells make specific proteins called 4E-BP. When the researchers knocked out ATF4 in cells or mice, they found tumor cells continued to build up those proteins and eventually died as a result of stress. This blocked tumor growth in mice with lymphomas and colorectal cancer. This study also found that when tumors in humans are driven by MYC, ATF4 and its protein partner 4E-BP are also overly expressed, which is further evidence that these findings may point to an approach that could work for humans.

"This shows us the potential impacts of targeting ATF4 in MYC-dependent tumors, something we're already studying. We're also working to confirm this approach will not cause any serious off-target effects," said lead author Feven Tameire, PhD, who conducted this research while she was a doctoral candidate at Penn.

Researchers say future studies will also focus on continuing to investigate why ATF4 works the way it does, which may help their understanding of whether there are other potential targets in the chain.

Story Source:

Materials provided by University of Pennsylvania School of Medicine. Note: Content may be edited for style and length.

Journal Reference:

1. Feven Tameire, Ioannis I. Verginadis, Nektaria Maria Leli, Christine Polte, Crystal S. Conn, Rani Ojha, Carlo Salas Salinas, Frank Chinga, Alexandra. M. Monroy, Weixuan Fu, Paul Wang, Andrew Kossenkov, Jiangbin Ye, Ravi K. Amaravadi, Zoya Ignatova, Serge Y. Fuchs, J. Alan Diehl, Davide Ruggero, Constantinos Koumenis. ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression. Nature Cell Biology, 2019; 21 (7): 889 DOI: 10.1038/s41556-019-0347-9